Why Did Buffett Sell the S&P 500?
Warren Buffett has always been an advocate of investing in…
Sell
23
IFRX Quote, Financials, Valuation and Earnings
Last price:
$1.15
Seasonality move
:
2.57%
Day range:
$1.14 - $1.28
52-week range:
$1.13 - $2.82
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
372.88x
P/B ratio:
1.21x
Volume:
346.1K
Avg. volume:
523.8K
1-year change:
-25.32%
Market cap:
$77.2M
Revenue:
$179.4K
EPS (TTM):
-$0.86
Analysts' Opinion
-
Consensus RatingInflaRx NV has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.17, InflaRx NV has an estimated upside of 697.1% from its current price of $1.15.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.98 representing 100% downside risk from its current price of $1.15.
Fair Value
-
According to the consensus of 5 analysts, InflaRx NV has 697.1% upside to fair value with a price target of $9.17 per share.
IFRX vs. S&P 500
-
Over the past 5 trading days, InflaRx NV has underperformed the S&P 500 by -8.76% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
InflaRx NV does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
InflaRx NV has grown year-over-year revenues for 0 quarters straight. In the most recent quarter InflaRx NV reported revenues of -$450.
Earnings Growth
-
InflaRx NV has grown year-over-year earnings for 0 quarters straight. In the most recent quarter InflaRx NV reported earnings per share of -$0.09.
Enterprise value:
22.2M
EV / Invested capital:
--
Price / LTM sales:
372.88x
EV / EBIT:
--
EV / Revenue:
122.29x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.42x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$3.4M
Return On Assets:
-48.45%
Net Income Margin (TTM):
-27536.81%
Return On Equity:
-56.78%
Return On Invested Capital:
-56.78%
Operating Margin:
-12405.26%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | $181.7K | $2.5K | -$450 | |
| Gross Profit | -- | -$507.6K | -$3.4M | -$296K | -$3M | |
| Operating Income | -$34.4M | -$48.6M | -$57.4M | -$14.3M | -$10.4M | |
| EBITDA | -$30.7M | -$45.5M | -$49.5M | -$17M | -$5.3M | |
| Diluted EPS | -$0.71 | -$0.86 | -$0.86 | -$0.30 | -$0.09 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $106.1M | $108.3M | $104.5M | $121M | $74.6M | |
| Total Assets | $108.5M | $141.7M | $109.8M | $132.9M | $79.1M | |
| Current Liabilities | $12.4M | $21.2M | $14M | $18.6M | $14.7M | |
| Total Liabilities | $12.7M | $22.5M | $15.1M | $19.5M | $15.2M | |
| Total Equity | $95.8M | $119.2M | $94.7M | $113.4M | $63.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$35.6M | -$40.9M | -$52.6M | -$11.6M | -$12.2M | |
| Cash From Investing | $20.4M | -$19.2M | $56.7M | $3.2M | $1.2M | |
| Cash From Financing | $2M | $57.4M | $418.3K | -$430.6K | $737.4K | |
| Free Cash Flow | -$35.8M | -$41M | -$52.6M | -$11.6M | -$12.3M | |
IFRX
Sector
Market Cap
$77.2M
$36.5M
Price % of 52-Week High
40.85%
44.66%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.9%
1-Year Price Total Return
-25.33%
-39.9%
Beta (5-Year)
1.979
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.28
200-day SMA
Sell
Level
$1.77
Bollinger Bands (100)
Sell
Level
1.5 - 2.5
Chaikin Money Flow
Sell
Level
-92.2M
20-day SMA
Sell
Level
$1.25
Relative Strength Index (RSI14)
Sell
Level
33.84
ADX Line
Sell
Level
32.83
Williams %R
Buy
Level
-93.7175
50-day SMA
Sell
Level
$1.85
MACD (12, 26)
Sell
Level
-0.16
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
270.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.4981)
Sell
CA Score
(Annual)
Level (-1.0401)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (5.7899)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Stock Forecast FAQ
In the current month, IFRX has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The IFRX average analyst price target in the past 3 months is $9.17.
-
Where Will InflaRx NV Stock Be In 1 Year?
According to analysts, the consensus estimate is that InflaRx NV share price will rise to $9.17 per share over the next 12 months.
-
What Do Analysts Say About InflaRx NV?
Analysts are divided on their view about InflaRx NV share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that InflaRx NV is a Sell and believe this share price will drop from its current level to $4.98.
-
What Is InflaRx NV's Price Target?
The price target for InflaRx NV over the next 1-year time period is forecast to be $9.17 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is IFRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for InflaRx NV is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IFRX?
You can purchase shares of InflaRx NV via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase InflaRx NV shares.
-
What Is The InflaRx NV Share Price Today?
InflaRx NV was last trading at $1.15 per share. This represents the most recent stock quote for InflaRx NV. Yesterday, InflaRx NV closed at $1.15 per share.
-
How To Buy InflaRx NV Stock Online?
In order to purchase InflaRx NV stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will SoundHound AI Stock Recover?
SoundHound AI (NASDAQ:SOUN) is a leading maker of artificial intelligence…
What Stocks Did Warren Buffett Just Buy?
In Q4 of last year, Warren Buffett added to or…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
AJINY alert for Mar 29
Ajinomoto [AJINY] is up 99.61% over the past day.
Buy
69
AGX alert for Mar 29
Argan [AGX] is up 19.83% over the past day.
Sell
24
AIR alert for Mar 29
AAR [AIR] is down 16.36% over the past day.
